New York, July 24, 2015 -- Moody's Investors Service commented that slowing sales of Tecfidera, the largest product of Biogen Inc. ("Biogen") increases the event risk of acquisitions. That said, there is currently no effect on Biogen's Baa1 senior unsecured rating or stable rating outlook based on strong financial flexibility.
Vollständigen Artikel bei Moodys lesen